Shenzhen Hepalink Pharmaceutical acquired 100% of the equity interest of Scientific Protein Laboratories (SLP), a U.S. leading manufacturer of heparin active pharmaceutical ingredients (APIs) for $2.075 billion Jan. 13. Hepalink also acquired Canadian biopharmaceutical manufacturer Prometic Life Sciences with $10 million at the end of 2012. Hepalink’s business focuses on R&D, production and sales of heparin APIs. Hepalink’s production was affected significantly, since its production of FDA-grade products was suspended in October 2013 for upgrading to meet the new regulations. This acquisition will greatly increase its production and allows it to enter the U.S. market. (Click Here For More - Chinese Language
)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?